In COVID-19 patients, the bradykinin–kallikrein pathway may counteract the effects of Ang II on the PAI-1 to tPA/uPA ratio in controlling acute inflammation by increasing the activity of kallikrein, a protease that converts kininogen to bradykinin [123,124]. Here, KLK4 is linked to COVID-19.